In the November/December 2015 issue of PharmaVOICE, Rhett Johnson explains that to achieve better value, the health care industry must define what value looks like and measure how effectively it is being produced. To read the article, click here.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.